Your session is about to expire
← Back to Search
Text-based Colorectal Cancer Prevention Pilot
N/A
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 150 days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a program that sends motivational text messages to patients who are not getting recommended colorectal cancer screenings. The messages aim to encourage these patients to get screened. The goal is to see if these reminders help more people follow through with their screenings.
Eligible Conditions
- Colorectal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 150 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~150 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Screening
Secondary study objectives
Phone Interview for refinement of Intervention
Side effects data
From 2019 Phase 4 trial • 136 Patients • NCT0258414045%
Decreased Creatinine Clearance
4%
Abdominal Discomfort
3%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
AEGIS
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Non-adherent interventionExperimental Treatment1 Intervention
Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
Group II: Non-adherent controlActive Control1 Intervention
Control subjects will receive no text intervention and a 150 day follow-up phone call.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Text Messaging
2016
Completed Phase 4
~3970
Find a Location
Who is running the clinical trial?
University of RochesterLead Sponsor
871 Previous Clinical Trials
549,700 Total Patients Enrolled